89 related articles for article (PubMed ID: 12901378)
1. Alteration of hepatitis A virus (HAV) particles by a soluble form of HAV cellular receptor 1 containing the immunoglobin-and mucin-like regions.
Silberstein E; Xing L; van de Beek W; Lu J; Cheng H; Kaplan GG
J Virol; 2003 Aug; 77(16):8765-74. PubMed ID: 12901378
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies.
Guo H; Ha S; Botten JW; Xu K; Zhang N; An Z; Strohl WR; Shiver JW; Fu TM
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793580
[TBL] [Abstract][Full Text] [Related]
3. An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV.
Guo H; Cho B; Hinton PR; He S; Yu Y; Ramesh AK; Sivaccumar JP; Ku Z; Campo K; Holland S; Sachdeva S; Mensch C; Dawod M; Whitaker A; Eisenhauer P; Falcone A; Honce R; Botten JW; Carroll SF; Keyt BA; Womack AW; Strohl WR; Xu K; Zhang N; An Z; Ha S; Shiver JW; Fu TM
Emerg Microbes Infect; 2023 Dec; 12(2):2275598. PubMed ID: 38078382
[TBL] [Abstract][Full Text] [Related]
4. Oligomers of hepatitis A virus (HAV) capsid protein VP1 generated in a heterologous expression system.
Nain A; Kumar M; Banerjee M
Microb Cell Fact; 2022 Apr; 21(1):53. PubMed ID: 35392916
[TBL] [Abstract][Full Text] [Related]
5. Reply to Das et al., "TIM1 (HAVCR1): an Essential 'Receptor' or an 'Accessory Attachment Factor' for Hepatitis A Virus?".
Costafreda MI; Kaplan G
J Virol; 2019 Jun; 93(11):. PubMed ID: 31092685
[No Abstract] [Full Text] [Related]
6. Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology.
Song J; Yu J; Prayogo GW; Cao W; Wu Y; Jia Z; Zhang A
Am J Transl Res; 2019; 11(3):1219-1229. PubMed ID: 30972157
[TBL] [Abstract][Full Text] [Related]
7. HAVCR1 (CD365) and Its Mouse Ortholog Are Functional Hepatitis A Virus (HAV) Cellular Receptors That Mediate HAV Infection.
Costafreda MI; Kaplan G
J Virol; 2018 May; 92(9):. PubMed ID: 29437974
[TBL] [Abstract][Full Text] [Related]
8. Potent neutralization of hepatitis A virus reveals a receptor mimic mechanism and the receptor recognition site.
Wang X; Zhu L; Dang M; Hu Z; Gao Q; Yuan S; Sun Y; Zhang B; Ren J; Kotecha A; Walter TS; Wang J; Fry EE; Stuart DI; Rao Z
Proc Natl Acad Sci U S A; 2017 Jan; 114(4):770-775. PubMed ID: 28074040
[TBL] [Abstract][Full Text] [Related]
9. The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection.
Pinkert S; Röger C; Kurreck J; Bergelson JM; Fechner H
J Virol; 2016 Jun; 90(12):5601-5610. PubMed ID: 27030267
[TBL] [Abstract][Full Text] [Related]
10. TIM-1 acts a dual-attachment receptor for Ebolavirus by interacting directly with viral GP and the PS on the viral envelope.
Yuan S; Cao L; Ling H; Dang M; Sun Y; Zhang X; Chen Y; Zhang L; Su D; Wang X; Rao Z
Protein Cell; 2015 Nov; 6(11):814-24. PubMed ID: 26487564
[TBL] [Abstract][Full Text] [Related]
11. The VP4 peptide of hepatitis A virus ruptures membranes through formation of discrete pores.
Shukla A; Padhi AK; Gomes J; Banerjee M
J Virol; 2014 Nov; 88(21):12409-21. PubMed ID: 25122794
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology and inhibitors of hepatitis A virus.
Debing Y; Neyts J; Thibaut HJ
Med Res Rev; 2014 Sep; 34(5):895-917. PubMed ID: 23722879
[TBL] [Abstract][Full Text] [Related]
13. Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice.
Xiao S; Brooks CR; Zhu C; Wu C; Sweere JM; Petecka S; Yeste A; Quintana FJ; Ichimura T; Sobel RA; Bonventre JV; Kuchroo VK
Proc Natl Acad Sci U S A; 2012 Jul; 109(30):12105-10. PubMed ID: 22773818
[TBL] [Abstract][Full Text] [Related]
14. Tim-1 regulates Th2 responses in an airway hypersensitivity model.
Curtiss ML; Gorman JV; Businga TR; Traver G; Singh M; Meyerholz DK; Kline JN; Murphy AJ; Valenzuela DM; Colgan JD; Rothman PB; Cassel SL
Eur J Immunol; 2012 Mar; 42(3):651-61. PubMed ID: 22144095
[TBL] [Abstract][Full Text] [Related]
15. A polymorphism in TIM1 is associated with susceptibility to severe hepatitis A virus infection in humans.
Kim HY; Eyheramonho MB; Pichavant M; Gonzalez Cambaceres C; Matangkasombut P; Cervio G; Kuperman S; Moreiro R; Konduru K; Manangeeswaran M; Freeman GJ; Kaplan GG; DeKruyff RH; Umetsu DT; Rosenzweig SD
J Clin Invest; 2011 Mar; 121(3):1111-8. PubMed ID: 21339644
[TBL] [Abstract][Full Text] [Related]
16. Determinants in 3Dpol modulate the rate of growth of hepatitis A virus.
Konduru K; Kaplan GG
J Virol; 2010 Aug; 84(16):8342-7. PubMed ID: 20534860
[TBL] [Abstract][Full Text] [Related]
17. Picornaviruses.
Tuthill TJ; Groppelli E; Hogle JM; Rowlands DJ
Curr Top Microbiol Immunol; 2010; 343():43-89. PubMed ID: 20397067
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of human T-cell immunoglobulin- and mucin-domain-containing molecule-4 in peripheral blood mononuclear cells from patients with system lupus erythematosus.
Zhao P; Xu L; Wang P; Liang X; Qi J; Liu P; Guo C; Zhang L; Ma C; Gao L
Cell Mol Immunol; 2010 Mar; 7(2):152-6. PubMed ID: 20140011
[TBL] [Abstract][Full Text] [Related]
19. The interaction of hepatitis A virus (HAV) with soluble forms of its cellular receptor 1 (HAVCR1) share the physiological requirements of infectivity in cell culture.
Silberstein E; Konduru K; Kaplan GG
Virol J; 2009 Oct; 6():175. PubMed ID: 19860892
[TBL] [Abstract][Full Text] [Related]
20. A simple and rapid Hepatitis A Virus (HAV) titration assay based on antibiotic resistance of infected cells: evaluation of the HAV neutralization potency of human immune globulin preparations.
Konduru K; Virata-Theimer ML; Yu MY; Kaplan GG
Virol J; 2008 Dec; 5():155. PubMed ID: 19094229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
